Guidant Tetra Stent Approval Opens Opportunity To Recoup Lost Market Share
This article was originally published in The Gray Sheet
Executive Summary
Guidant is looking to its Multi-Link Tetra fourth-generation coronary stent platform to recoup a recent loss in U.S. stent market share, following a drop-off in demand for its Tri-Star stent.
You may also be interested in...
Guidant
Firm starts a 200-patient, 22-site clinical trial Dec. 4 evaluating the fifth-generation Multi-Link Penta coronary stent, which features enhanced retention and conformability. Guidant launched its fourth-generation Multi-Link Tetra on Oct. 3 (1"The Gray Sheet" Oct. 9, 2000, p. 16)
Guidant
Firm starts a 200-patient, 22-site clinical trial Dec. 4 evaluating the fifth-generation Multi-Link Penta coronary stent, which features enhanced retention and conformability. Guidant launched its fourth-generation Multi-Link Tetra on Oct. 3 (1"The Gray Sheet" Oct. 9, 2000, p. 16)
Dick Cheney
Republican vice presidential nominee is treated with Guidant's MultiLink Tetra coronary stent Nov. 22 at the George Washington University Hospital in Washington, D.C., according to company officials. The fourth-generation stent received PMA supplement approval Oct. 3 (1"The Gray Sheet" Oct. 9, 2000, p. 16)